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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
eicosapentanoic acid (EPA) and “reduces the AA/EPA ratio in blood. 
A high AA/EPA level is a risk factor in the development of attention 
difficulties in children with ADHD-like symptoms” pursuant to Article 14 
of Regulation (EC) No 1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Minami Nutrition Health BVBA, submitted pursuant to Article 14 of Regulation 
(EC) No 1924/2006 via the Competent Authority of Belgium, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to 
eicosapentaenoic acid (EPA) and “reduces the AA/EPA ratio in blood. A high AA/EPA level is a risk factor in 
the development of attention difficulties in children with attention deficit hyperactivity disorder (ADHD)-like 
symptoms”. The food constituent, EPA, which is the subject of the health claim, is sufficiently characterised. The 
claimed effect proposed by the applicant is “reduces the AA/EPA ratio in blood. A high AA/EPA level is a risk 
factor in the development of attention difficulties in children with ADHD-like symptoms. These children are also 
characterised  by  less  hyperactivity  and/or  coexisting  oppositional  behaviour”.  Upon  a  request  by  EFSA  for 
clarification, the applicant indicated that the disease was ADHD, which is classified as such in accordance with 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), that the risk factor for the disease was an 
elevated AA/EPA ratio in blood, and that the target population for the claim was children with diagnosis of 
ADHD.  The  Panel  considers that the  evidence provided does not establish that  reducing  the AA/EPA ratio 
reduces the risk of ADHD in children, and considers that the target population is a diseased population (i.e. 
children with ADHD). The Panel concludes that the claimed effect relates to the treatment of a disease, and that 
therefore the health claim does not comply with the criteria laid down in Regulation (EC) No 1924/2006. 
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SUMMARY 
Following an application from Minami Nutrition Health BVBA, submitted pursuant to Article 14 of 
Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the EFSA Panel on Dietetic 
Products,  Nutrition  and  Allergies  (NDA)  was  asked  to  deliver  an  opinion  on  the  scientific 
substantiation of a health claim related to eicosapentaenoic acid (EPA) and “reduces the AA/EPA 
ratio in blood. A high AA/EPA level is a risk factor in the development of attention difficulties in 
children with ADHD-like symptoms”. The scope of the application was proposed to fall under a 
health claim referring to disease risk reduction. 
The  Panel  considers  that  the  food  constituent,  EPA,  which  is  the  subject of the health claim, is 
sufficiently characterised. 
The claimed effect proposed by the applicant is “reduces the AA/EPA ratio in blood. A high AA/EPA 
level is a risk factor in the development of attention difficulties in children with  attention deficit 
hyperactivity  disorder  (ADHD)-like  symptoms.  These  children  are  also  characterised  by  less 
hyperactivity  and/or  coexisting  oppositional  behaviour”.  The  target  population  proposed  by  the 
applicant is “children 5-13 years of age with ADHD-like symptoms and low blood levels of omega-3 
fatty acids”.  
Upon a request by EFSA for clarification in relation to the proposed claimed effect, the validity of the 
risk factor proposed for the disease, and the target population, the applicant indicated that the disease 
was ADHD, which is classified as such in accordance with the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV), that the risk factor for the disease was an elevated AA/EPA ratio in 
blood, and that the target population for the claim was children with diagnosis of ADHD.  
No evidence was provided by the applicant to substantiate that the AA/EPA ratio plays a role in the 
development of ADHD, that the AA/EPA ratio can predict the incidence of ADHD, or that lowering 
the AA/EPA ratio can lower the risk of ADHD. 
The Panel considers that the evidence provided does not establish that reducing the AA/EPA ratio 
reduces the risk of ADHD in children. 
The Panel notes that the target population for the claim is a diseased population (i.e. children with 
ADHD).  
The Panel concludes that the claimed effect relates to the treatment of a disease, and that therefore the 
health claim does not comply with the criteria laid down in Regulation (EC) No 1924/2006. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4 harmonises the provisions that relate to nutrition and health claims , 
and establishes rules governing the Community authorisation of health claims made on foods.  As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of  
this Regulation, are authorised in accordance with this Regulation , and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular,  Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk  claims  and  claims  referring  to  children’s  development  and  health  in  a  Community  list  of 
permitted claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any  supplementary  information  supplied  by  the  applicant  available  to  the  European  Food  Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
  The application was received on 07/05/2012. 
  The scope of the application was proposed to fall under a health claim referring to disease 
risk reduction. 
  On 14/06/2012, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
  On 12/10/2012, EFSA received the missing information as submitted by the applicant. 
  The scientific evaluation procedure started on 26/10/2012. 
  On 30/11/2012, the NDA Panel agreed on a list of questions for the applicant to provide 
additional  information  to  accompany  the  application,  and  the  clock  was  stopped  on 
30/11/2012, in compliance with Article 16(1) of Regulation (EC) No 1924/2006. 
  On 07/02/2013, EFSA received the requested information and the clock was restarted on 
07/02/2013, in compliance with Article 16(1) of Regulation (EC) No 1924/2006. 
  During  its  meeting  on  21/03/2013,  the  NDA  Panel,  having  evaluated  the  data  submitted, 
adopted  an  opinion  on  the  scientific  substantiation  of a health claim related to  EPA and 
“reduces the AA/EPA ratio in blood. A high AA/EPA level is a risk factor in the development 
of attention difficulties in children with ADHD-like symptoms”. 
TERMS OF REFERENCE 
EFSA  is  requested  to  evaluate  the  scientific  data  submitted  by  the  applicant  in  accordance  with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: EPA and “reduces the AA/EPA 
ratio in blood. A high AA/EPA level is a risk factor in the development of attention difficulties in 
children with ADHD-like symptoms”. 
EFSA DISCLAIMER 
The  present  opinion  does  not  constitute,  and  cannot  be  construed  as,  an  authorisation  for  the 
marketing of eicosapentanoic acid, a positive assessment of its safety, nor a decision on whether 
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. EPA and “reduces AA/EPA ratio in blood in children with ADHD” 
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eicosapentanoic acid is, or is not, classified as a foodstuff. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. EPA and “reduces AA/EPA ratio in blood in children with ADHD” 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Minami Nutrition Health BVBA, Leugstraat 51, 2630 Aartselaar, 
Belgium. 
Food/constituent as stated by the applicant 
According  to  the  applicant,  the  food  constituent  that  is  the  subject  of  the  health  claim  is 
eicosapentaenoic acid (EPA). 
Health relationship as claimed by the applicant 
According to the applicant, EPA reduces the AA/EPA fatty acid ratio in blood. Such ratio is claimed 
by the applicant to correlate to attention performance in children with attention deficit hyperactivity 
disorder (ADHD)-like symptoms. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “EPA has been shown to 
reduce the AA/EPA ratio in blood. A high AA/EPA level is a risk factor in the development of 
attention difficulties in children with ADHD-like symptoms. These children are also characterised by 
less hyperactivity and/or coexisting oppositional behaviour”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed an intake of 500 mg EPA per day with meals. The target population 
proposed by the applicant is children 5-13 years of age with ADHD-like symptoms and low blood 
levels of omega-3 fatty acids. 
ASSESSMENT 
1.  Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is eicosapentaenoic acid (EPA).  
EPA is a 20-carbon fatty acid with five double bonds of the omega-3 series (omega-3 long-chain 
polyunsaturated fatty acid) which is a well recognised nutrient naturally present in foods from animal 
sources, especially oily fish. EPA is proposed to be used in the form of triglycerides, ethyl esters or 
phospholipids for addition to food supplements. EPA is measurable in foods by established methods.  
The  Panel  considers  that  the  food  constituent,  EPA,  which  is  the  subject of the health claim, is 
sufficiently characterised.  
2.  Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “reduces the AA/EPA ratio in blood. A high AA/EPA 
level  is  a  risk  factor  in  the  development  of  attention  difficulties  in  children  with  ADHD-like 
symptoms. These children are also characterised by less hyperactivity and/or coexisting oppositional 
behaviour”.  The  target  population  proposed  by  the  applicant  is  “children 5-13 years of age with 
ADHD-like symptoms and low blood levels of omega-3 fatty acids”.  
During the evaluation process,  EFSA requested clarification from the applicant in relation to the 
disease that is the subject of the health claim, in relation to the validity of the risk factor proposed for 
the disease, and in relation to the proposed target population, noting that “attention difficulties” is not 
a well-defined disease and that “children with ADHD-like symptoms” had not been characterised in 
relation to the presence or absence of disease. The applicant clarified that the disease was ADHD, EPA and “reduces AA/EPA ratio in blood in children with ADHD” 
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which  is  classified  as  such  in  accordance  with  the  Diagnostic  and  Statistical  Manual  of  Mental 
Disorders (DSM-IV), that the risk factor for the disease was an elevated AA/EPA ratio in blood, and 
that the target population for the claim was children with diagnosis of ADHD.  
The applicant claims that an elevated AA/EPA ratio in blood is a risk factor in the development of 
ADHD. The evidence provided to support this statement consisted of four case-control studies in 
which the AA/EPA ratio in children with ADHD was significantly higher than in healthy controls 
(Stevens et al., 1995, Chen et al., 2004; Antalis et al., 2006, Colter et al., 2008). The Panel notes that 
no evidence was provided by the applicant that the AA/EPA ratio plays a role in the development of 
ADHD; that the AA/EPA ratio can predict the incidence of ADHD; or that lowering the AA/EPA 
ratio can lower the risk of ADHD; and that reverse causality cannot be excluded from these studies.  
The Panel considers that the evidence provided does not establish that reducing the AA/EPA ratio 
reduces the risk of ADHD in children. 
The Panel notes that the target population for the claim is a diseased population (i.e. children with 
ADHD).  
The Panel concludes that the claimed effect relates to the treatment of a disease, and that therefore the 
health claim does not comply with the criteria laid down in Regulation (EC) No 1924/2006. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
  The  food  constituent,  EPA,  which  is  the  subject  of  the  health  claim,  is  sufficiently 
characterised. 
  The claimed effect proposed by the applicant is “reduces the AA/EPA ratio in blood. A high 
AA/EPA level is a risk factor in the development of attention difficulties in children with 
ADHD-like  symptoms.  These  children  are  also  characterised  by  less  hyperactivity  and/or 
coexisting  oppositional  behaviour”.  The  target  population  proposed  by  the  applicant  is 
“children 5-13 years of age with ADHD-like symptoms and low blood levels of omega-3 fatty 
acids”. 
  The claimed effect relates to the treatment of a disease, and that therefore the health claim 
does not comply with the criteria laid down in Regulation (EC) No 1924/2006.  
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on EPA and “reduces the AA/EPA ratio in blood. A high AA/EPA level is a 
risk  factor  in  the  development  of  attention  difficulties  in  children  with  ADHD-like  symptoms” 
pursuant to Article 14 of Regulation (EC) No 1924/2006 (Claim Serial No: 0350_BE). May 2012. 
Submitted by Minami Nutrition Health BVBA. 
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GLOSSARY / ABBREVIATIONS 
AA    arachidonic acid 
ADHD   attention deficit hyperactivity disorder 
EPA    eicosapentaenoic acid 
 